In 2000, when the concept of ‘regenerative medicine’ was still obscure to many, Cellontech established ‘RMS(Regenerative Medical System)’ with its ‘Chondron’ (gel-type ACI) being the first cell therapy product to be launched and successfully commercialized in Korea. With ‘Chondron’, Cellontech has opened a new chapter in Regenerative Medicine history.

Focusing on the essential elements of ‘cell’ and ‘biomaterial’, Cellontech is committed to the development and commercialization of innovative therapies for people suffering from Osteoarthritis and impared cartilage, bone, skin or tissues. Currently, our vanguard product portfolio is composed of regenerative medicine products, a cord blood bank and stem cell therapy.

Holding its own ground at the core of evergrowing biotech industry, Cellontech aims to expand its portfolio by developing organ-regenerating biomaterials, including NCB, DDS and CDV. Bolstered by the unchallenged expertise and leadership, Cellontech seeks to transform the lives of patients and further materialize the lifetime health of patients.